RxDoctor Payments Data

Susan Spence, PA

Physician Assistant · Lexington, KYNPI 1497537336

Payments from drug & device makers

$2,878in general payments, 2019–2025

Across 129 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$658
  • Ardelyx, Inc.$438
  • Astellas Pharma US Inc$350
  • Sumitomo Pharma America, Inc.$278
  • Exeltis, USA Inc.$193
  • Lilly USA, LLC$167
  • plus $794 from 17 others

What the payments were for

  • Food & beverage$2,69394%
  • Education$1856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,878 in reported general payments places this provider in the 80th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,087
Medicare patients
22
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide12$10,460
VraylarCariprazine Hcl11$9,849
VeozahFezolinetant13$7,821
Clobetasol Propionate20$246
Fluconazole11$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Vraylar$658$20,30923 claims
Astellas Pharma US IncVeozah$350$7,82113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →